% | $
Quotes you view appear here for quick access.

công ty Aastrom Biosciences Message Board

  • hwmccusker hwmccusker Dec 12, 2012 10:05 AM Flag

    New CEO

    The Bottom Line: Interim CEO, Dan Orlando brings a depth of experience in the development and commercialization of cardiovascular and metabolic therapies that will help ASTM to continue moving forward. Mr. Mayleben will continue to support the transition to a permanent CEO. I am not the only one to say – “Great Move”; Steve Brozak of WBB Securities also signaled the same message in a call … “Dan past deal structure successes and experience should further focus … ASTM’s ability to drive significant value to this disease state franchise”! ASTM closed DOWN yesterday … at $1.30 but, is up $0.02 to $1.32 at the open with a tighter mid-day range of $1.29 – $1.32 but, is settling at $1.30. I have NOT given up as ASTM has been getting “hammered” on filings of stock sales but, they are … related to the warrant swaps … which other companies have been … unable … to recognize with their “muddied” balance sheets! I have maintained a “BUY” in this market and at this pricing because of the late stage trial status even with a dwindling RegMed universe pricing and visibility. As the BOD … fulfills its responsibility … they will make this appointment permanent in the New Year !

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies